StockpollyBeta
Get App
Popularity #523
RARE · NASDAQ · Biotechnology

Ultragenyx Pharmaceutical (RARE)

Develops and commercializes therapies for serious rare and ultra-rare genetic diseases.

$15.65
After-hours close+0.04 (+0.26%)
At close$15.61(+6.55%)

  1. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

    GlobeNewsWire

  2. ULTRA-RARE MCA CENTENAIRE, MONACO'S FIRST SUPERCAR, OFFERED AT BROAD ARROW'S 2026 ZOUTE CONCOURS AUCTION

    GlobeNewsWire

  3. RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy

    Zacks Investment Research

  4. Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?

    Zacks Investment Research

  5. Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of FAYUVI as First Treatment for Sanfilippo Syndrome Type A Transcript

    Seeking Alpha

  6. Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)

    GlobeNewsWire

  7. US FDA approves Ultragenyx's gene therapy for rare disorder

    Reuters

  8. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

    PRNewsWire

  9. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

    GlobeNewsWire

  10. Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report?

    Zacks Investment ResearchMarket move

  11. RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals

    Zacks Investment ResearchClinical

  12. Ultragenyx Forced To Cut Costs After Disappointing Phase 3 Results

    BenzingaClinical

  13. Ultragenyx Stock Sinks 47% on Drug Trial Failure. Why Wall Street Isn't Giving Up Yet.

    BarronsClinical

  14. Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial

    ReutersClinical

  15. Ultragenyx's rare disease drug fails in late-stage trial; shares plunge

    ReutersClinical

  16. Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome

    GlobeNewsWireClinical

  17. Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease

    GlobeNewsWireClinical

  18. 164,813 Shares in Ultragenyx Pharmaceutical Inc. $RARE Bought by Deutsche Bank AG

    Defense WorldOwnership

  19. RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos

    Zacks Investment ResearchClinical

  20. Ultragenyx Nabs FDA Nod for First Gene Therapy

    BenzingaClinical